Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in COPD: Effects on Airway Inflammation and Epithelial Immune Response
2024-511730-12-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Change in airway eosinophil counts. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-511730-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511730-12-00.